Posts Tagged ‘trial’

sites.google.com Sleeve Gastrectomy Versus Mini-Gastric Bypass for the Treatment of Non-Morbid Obese Diabetic Patients: a Randomized Trial Presenter: WJ Lee (Min-Sheng General Hospital, Taoyuan, Taiwan) Co-authors: J. Chen1, K. Ser Min-Sheng General Hospital, Taoyuan, Taiwan Background Bariatric Surgery leads to a dramatic improvement in morbid obesity associated type 2 Diabetes Mellitus (T2DM) but the mechanism remains speculative. This study compared the laparoscopic sleeve gastrectomy (LSG) and Mini-Gastric Bypass (MGB) in the treatment of type 2 Diabetes Mellitus, and to test the fore-gut hypothesis. Methods Patients aged 30 to 60 years, with poorly controlled type 2 Diabetes Mellitus (HbA1C gt 7.5%) and BMI between 35 and 25 were included and randomized to laparoscopic sleeve gastrectomy and Mini-Gastric Bypass. The end point is type 2 Diabetes Mellitus resolution, defined by fasting plasma glucose lt 126 mg/dl and HbA1C lt 6.5%. Results 40 patients with a mean BMI 29 (24-34), age 45 (34-58) and HbA1C of 10.0% (8.0-15) were randomized to either laparoscopic sleeve gastrectomy (n = 20) or Mini-Gastric Bypass (n = 20). All procedures were successfully carried out with no deaths or major complication in either group. Minor complication occurred in 4 patients (10%). There was no difference in basic and peri-operative clinical parameters between the two groups. Minimum follow-up was 12 months (from 14 to 28 months). After surgery, both groups experienced a rapid decrease …

Avandia On Trial: Glaxo’s Defense III
More on the FDA panel that could decide the diabetes drug’s fate.

Living with type 2 diabetes is a long road to walk alone. Help us explore pathways to diabetes management. You or a loved one may be eligible to participate in a clinical research study of an investigational diabetes medication taken as a pill. For more information, visit PathwaysForDiabetes.com

Positive top-line results from Phenomix’ Phase 3 trial of dutogliptin for Type 2 diabetes mellitus
Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus placebo for the treatment of patients with Type 2 diabetes mellitus. Dutogliptin is Phenomix’ internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor.

Accumetrics completes enrollment phase of GRAVITAS clinical trial
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.